Abcam, ab151751, Anti-SLC17A1 antibody [EPR9614]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal SLC17A1 antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR9614,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please
contact us
for more information.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purity-Tissue culture supernatant, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SLC17A1 also known as NPT1 or sodium-dependent phosphate transport protein 1 is a protein that functions primarily as a transporter. It facilitates the reabsorption of phosphate ions in the renal proximal tubules. This protein has a molecular mass of approximately 54 kDa and is mainly expressed in the kidney. The presence of SLC17A1 in renal tissues plays an important role in maintaining plasma phosphate levels which is essential for bone health and various metabolic processes. Additionally SLC17A1 belongs to the solute carrier family 17 acting as an important mediator in phosphate homeostasis.
Biological function summary
This transporter plays a significant role in the regulation of phosphate balance in the body. By functioning in the renal system SLC17A1 affects phosphate excretion and reabsorption which directly influences mineral and bone metabolism. It operates as part of a greater network involving other phosphate transporters and channels in the kidney. This network ensures that the body maintains proper phosphate levels necessary for critical cellular functions and skeletal integrity. The efficient operation of SLC17A1 in this context is essential to the homeostatic maintenance of serum phosphate concentrations.
Pathways
SLC17A1 is an important component of phosphate homeostasis and mineral metabolism pathways. It interacts with other proteins such as SLC34A1 another sodium-dependent phosphate transporter and plays a part in the renal tubular reabsorption of phosphate. These pathways are vital in regulating the levels of phosphate which is integral for energy production nucleotide synthesis and signaling processes in cells. The transporter collaborates with other elements in the parathyroid hormone-related pathways impacting overall calcium homeostasis and bone remodeling.
SLC17A1 is closely linked to conditions such as phosphate wasting disorders and renal tubular reabsorption abnormalities. Mutations or dysfunctions in the SLC17A1 gene may lead to diseases like hypophosphatemia characterized by low serum phosphate levels and associated bone disorders such as rickets and osteomalacia. The protein's involvement in these conditions often overlaps with interactions alongside other transport proteins like SLC20A1 affecting phosphate absorption and systemic phosphate balance. Understanding this relationship is important for developing therapeutic strategies aimed at treating phosphate-related disorders.